# Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma

> **NCT06934382** · PHASE1 · RECRUITING · sponsor: **Stephan Grupp MD PhD** · enrollment: 33 (estimated)

## Conditions studied

- T-Cell Acute Lymphoblastic Leukemia/Lymphoma

## Interventions

- **BIOLOGICAL:** Allogeneic anti-CD7 CAR-T cells (BEAM-201)

## Key facts

- **NCT ID:** NCT06934382
- **Lead sponsor:** Stephan Grupp MD PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-29
- **Primary completion:** 2029-05-30
- **Final completion:** 2031-05-30
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2025-12-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06934382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06934382, "Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06934382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*